DK0761650T3 - Termostabil og holdbar krystalmodifikation af N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamid og fremgangsmåde til dets fremstilling - Google Patents

Termostabil og holdbar krystalmodifikation af N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamid og fremgangsmåde til dets fremstilling

Info

Publication number
DK0761650T3
DK0761650T3 DK96112489T DK96112489T DK0761650T3 DK 0761650 T3 DK0761650 T3 DK 0761650T3 DK 96112489 T DK96112489 T DK 96112489T DK 96112489 T DK96112489 T DK 96112489T DK 0761650 T3 DK0761650 T3 DK 0761650T3
Authority
DK
Denmark
Prior art keywords
hydroxypyrrolidin
thermostable
acetamide
diphenyl
phenyl
Prior art date
Application number
DK96112489T
Other languages
Danish (da)
English (en)
Inventor
Inge Dr Stein
Holger Beeres
Klaus Dr Beschmann
Steffen Dr Neuenfeld
Andrew Dr Barber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK0761650T3 publication Critical patent/DK0761650T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK96112489T 1995-08-26 1996-08-02 Termostabil og holdbar krystalmodifikation af N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamid og fremgangsmåde til dets fremstilling DK0761650T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19531464A DE19531464A1 (de) 1995-08-26 1995-08-26 N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid

Publications (1)

Publication Number Publication Date
DK0761650T3 true DK0761650T3 (da) 2002-02-18

Family

ID=7770485

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96112489T DK0761650T3 (da) 1995-08-26 1996-08-02 Termostabil og holdbar krystalmodifikation af N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamid og fremgangsmåde til dets fremstilling

Country Status (25)

Country Link
US (1) US6060504A (zh)
EP (1) EP0761650B1 (zh)
JP (3) JP5023273B2 (zh)
KR (1) KR100436254B1 (zh)
CN (1) CN1081631C (zh)
AR (1) AR004679A1 (zh)
AT (1) ATE207895T1 (zh)
AU (1) AU716615B2 (zh)
BR (1) BR9603540A (zh)
CA (1) CA2184049C (zh)
CZ (1) CZ287783B6 (zh)
DE (2) DE19531464A1 (zh)
DK (1) DK0761650T3 (zh)
ES (1) ES2165948T3 (zh)
HU (1) HU226667B1 (zh)
MX (1) MX9603606A (zh)
NO (1) NO307048B1 (zh)
PL (1) PL187691B1 (zh)
PT (1) PT761650E (zh)
RU (1) RU2174976C2 (zh)
SI (1) SI0761650T1 (zh)
SK (1) SK282437B6 (zh)
TW (1) TW513407B (zh)
UA (1) UA41978C2 (zh)
ZA (1) ZA967200B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1828399A (en) * 1997-12-22 1999-07-12 Alza Corporation Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
JP2005531557A (ja) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
EP2636407A3 (en) 2007-03-30 2013-11-06 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
EP2284987B1 (en) * 2009-08-12 2019-02-06 Braun GmbH Method and device for adjusting the frequency of a drive current of an electric motor
WO2011136905A2 (en) * 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CA3047325A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
SK282437B6 (sk) 2002-02-05
KR100436254B1 (ko) 2005-01-25
JP2012246321A (ja) 2012-12-13
DE19531464A1 (de) 1997-02-27
SI0761650T1 (en) 2002-04-30
AU716615B2 (en) 2000-03-02
HUP9602346A3 (en) 1998-01-28
JP2009046501A (ja) 2009-03-05
RU2174976C2 (ru) 2001-10-20
PL187691B1 (pl) 2004-09-30
AU6214996A (en) 1997-03-06
TW513407B (en) 2002-12-11
PT761650E (pt) 2002-04-29
EP0761650A1 (de) 1997-03-12
AR004679A1 (es) 1999-03-10
US6060504A (en) 2000-05-09
CA2184049A1 (en) 1997-02-27
CZ243496A3 (en) 1997-03-12
NO963526D0 (no) 1996-08-23
SK108996A3 (en) 1997-06-04
DE59608050D1 (de) 2001-12-06
EP0761650B1 (de) 2001-10-31
CN1151986A (zh) 1997-06-18
ZA967200B (en) 1997-03-03
JP5023273B2 (ja) 2012-09-12
CZ287783B6 (en) 2001-02-14
ES2165948T3 (es) 2002-04-01
MX9603606A (es) 1997-03-29
CA2184049C (en) 2007-10-02
KR970010744A (ko) 1997-03-27
HU9602346D0 (en) 1996-10-28
ATE207895T1 (de) 2001-11-15
HUP9602346A2 (en) 1997-09-29
CN1081631C (zh) 2002-03-27
NO307048B1 (no) 2000-01-31
HU226667B1 (en) 2009-06-29
BR9603540A (pt) 1998-05-12
NO963526L (no) 1997-02-27
PL315799A1 (en) 1997-03-03
UA41978C2 (uk) 2001-10-15
JPH09110830A (ja) 1997-04-28

Similar Documents

Publication Publication Date Title
DK0761650T3 (da) Termostabil og holdbar krystalmodifikation af N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamid og fremgangsmåde til dets fremstilling
NO20000227L (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmåte for dens fremstilling og dens anvendelse
DK1398A (da) Antifungalt middel, forbindelse til dette, fremgangsmåde til fremstilling af denne og metode til dets anvendelse
DK0828840T3 (da) Alkalisk cellulase og fremgangsmåde til fremstilling deraf
NO982055L (no) 2-alkylpyrrolidiner
KR950701085A (ko) 내부 고정 스페이서를 이용하는 액정광 밸브 및 이의 사용 방법(Improved Liquid Crystal Light Valves Using Internal, Fixed Spacers and Method of Incorporating Same)
DK0839132T3 (da) Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[
AU3829300A (en) Method and apparatus for telecommunications using internet protocol
DE69618661D1 (de) Flüssigkristalline (meth)acrylat-verbindungen, zusammensetzung und verfahren dafür
AU4196599A (en) Apparatus and method employing a single laser for removal of hair, veins and capillaries
ATE214275T1 (de) Verwendung von n-methyl-n-((1s)-1-phenyl-2-((3s)- 3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl- acetamid hydrochlorid zur herstellung von arzneimitteln zur behandlung von entzündlichen darmerkrankungen
DK0773984T3 (da) Enzymholdig granuleret substans og fremgangsmåde til fremstilling heraf
EE03242B1 (et) Virde pideva keetmise meetod, meetod sellest virdest õlle valmistamiseks ja selle meetodiga valmistatud õlu
NO20021423L (no) Beströket, optisk lysnet trykkpapir og fremgangsmåte for fremstilling derav
NO992162D0 (no) FremgangsmÕte og innretning for rensing av blodplasma
NO975076D0 (no) Farmasöytisk preparat som inneholder tiagabinhydroklorid, og fremgangsmåte for dets fremstilling
DK0727416T3 (da) Substituerede benzensulfonylurinstoffer og -thiourinstoffer, og fremgangsmåde til deres fremstilling, deres anvendelse som
FI944182A0 (fi) Yhtenäiskiteitä sisältävä koostumus, menetelmä senYhtenäiskiteitä sisältävä koostumus, menetelmä sen valmistamiseksi ja sen käyttö valmistamiseksi ja sen käyttö
AU6801596A (en) Method and apparatus for treatment of neurogenic diabetes mellitus, and other conditions
ATE303361T1 (de) Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl)- 2,2- diphenylacetamid
AU4034699A (en) Method for racemization of optically active amines
AU6871800A (en) Method of piercing membrane and apparatus therefor
NO20001822D0 (no) Ny fremgangsmåte for fremstilling av mellomprodukter for inhibitorer av enkefalinase og angiotensinomdannende enzym, og mellomprodukter derav
PT968212E (pt) Metodo para preparar (1s.4r)-1-azabiciclo¬2.2.1|heptan-3-ona e (1r,4s)-1-azabiciclo¬2.2.1|heptan-3-ona
DE69603306T2 (de) N-(alpha-alkylbenzyliden)-alpha-phenylalkylamin, seine Verwendung, Verfahren zu seiner Herstellung und Verfahren zur Herstellung von Zwischenprodukten dafür